Trillium Therapeutics

$11.46
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.83 (-6.76%) Today
+$0.01 (+0.09%) As of 1:00 PM UTC after-hours

Why Robinhood?

You can buy or sell TRIL and other stocks, options, and ETFs commission-free!

About TRIL

Trillium Therapeutics Inc. Common Shares, also called Trillium Therapeutics, is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. Its pipeline is comprised of TTI-621, TTI-622, and TTI-10001 (Sting Agonist). The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. The listed name for TRIL is Trillium Therapeutics Inc. Common Shares.

CEO
Jan Skvarka
Employees
29
Headquarters
Mississauga, Ontario
Founded
2004
Market Cap
1.15B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.27M
High Today
$12.32
Low Today
$11.36
Open Price
$12.17
Volume
1.88M
52 Week High
$20.96
52 Week Low
$2.50

TRIL Earnings

-$1.07
-$0.71
-$0.36
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 10, Pre-Market

You May Also Like

TVC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure